New combo aims to wipe out stubborn leukemia cells
NCT ID NCT03128879
First seen Nov 21, 2025 · Last updated Jun 16, 2026 · Updated 24 times
Summary
This study tests whether adding venetoclax to ongoing ibrutinib or acalabrutinib treatment can eliminate remaining leukemia cells in people with high-risk chronic lymphocytic leukemia (CLL). Participants must have been on their current therapy for at least 12 months and still have detectable disease. The goal is to achieve undetectable minimal residual disease (MRD) in the bone marrow, which means no cancer cells can be found with sensitive testing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.